|Articles|July 30, 2014
- NSCLC (Issue 3)
- Volume 3
- Issue 1
<em>RICTOR</em> Amplification in Lung Cancer
Author(s)Bilal Piperdi, MD
Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.
Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, director, Lung Cancer Program, Montefiore Einstein Center for Cancer Care, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked atRICTORamplification to define a subset of patients with lung cancer.
Read more about defining subsets and predicting outcomes in lung cancer > >
Articles in this issue
over 11 years ago
Update on Next-Generation Therapies for NSCLCover 11 years ago
Adverse Events Associated With CO-1686over 11 years ago
Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLCover 11 years ago
Peer Discussion on Maintenance Therapy in NSCLCover 11 years ago
Trials of Anti-PD-L1 in NSCLC Are Well Under WayRelated Content
Advertisement
